Seminars in Hematology
Volume 46, Supplement 3 , Pages S16-S21, April 2009

Practical Considerations for the Management of Patients in the Tyrosine Kinase Inhibitor Era

  • Michael O'Dwyer

      Affiliations

    • Department of Haematology, University Hospital Galway, National University of Ireland, Galway, Ireland
    • Corresponding Author InformationAddress correspondence to Michael O'Dwyer, MD, FRCPI, FRCPath, Professor of Haematology, University Hospital Galway, National University of Ireland, Galway, Ireland
    • ,
  • Ehab Atallah

      Affiliations

    • Division of Neoplastic Diseases and Related Disorders, Medical College of Wisconsin, Milwaukee, WI

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals.

 STATEMENT OF CONFLICT OF INTEREST: Drs O'Dwyer and Atallah have received honoraria from Novartis Pharmaceuticals Corp.

PII: S0037-1963(09)00021-3

doi:10.1053/j.seminhematol.2009.01.010

Seminars in Hematology
Volume 46, Supplement 3 , Pages S16-S21, April 2009

Article Tools

* Image Usage & Resolution